Orchid Pharma Ltd

(ORCHPHARMA)

Orchid Pharma Ltd. is a globally recognized pharmaceutical company based in Chennai, India, specialized in the development, manufacture and marketing of diverse bulk actives formulations and nutraceuticals. The company’s core expertise covers manufacturing Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms, as well as drug discovery. It is the youngest Indian pharmaceutical company to be awarded the ISO 9002 certification.In 1998 they received approval from the Drug Controller of India (DCI) for the manufacture and export of the main ingredient of Viagra.By 2000 they acquired a manufacturing plant in Aurangabad and in 2004 signed a pact with Par Pharmaceuticals Inc. to market oral cephalosporin formulations in the US market.In 2006 a deal with Biovitrum was signed and two years later the company had approval from the US FDA for their abbreviated new drug application. They entered the Japanese generics market with the creation of awholly owned subsidiary and also inked an agreement with Merck & Co. The company increased their stake in Diakron Pharmaceuticals Inc. up to 76.4 and over the years have made pacts with numerous companies in both drug discovery and commercialization. In 2017 they launched a new product and as of 2020 became a subsidiary of Dhanuka Laboratories Ltd with funding from a special purpose vehicle. Furthermore the company has subscribed to OrBion Pharmaceuticals Pvt. Ltd. and incorporated Orchid BioPharma Ltd, becoming an Associate of the company.

Share Price: ₹1477.60 per share as on 21 Nov, 2024 04:01 PM
Market Capitalisation: ₹7,308.12Cr as of today
Revenue: ₹222.70Cr as on September 2024 (Q3 24)
Net Profit: ₹25.90Cr as on September 2024 (Q3 24)
Listing date: 12 May, 1995
Chairperson Name: Ram Gopal Agarwal